GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024
/PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody...